Lyra Therapeutics, Inc. (LYRA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Lyra Therapeutics, Inc. reported revenue of $398.0K, down 74.1% from the prior year. The company ran a net loss, with a net margin of -7266.1%. It held $36.11M in total assets against $46.83M in total liabilities.
Key ratios (FY2025)
-7794.5%
Operating margin
-7266.1%
Net margin
-74.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $398.0K | $1.53M | $1.56M | $1.36M | $285.0K | — | — | — |
| Operating Income | -$31.02M | -$96.35M | -$67.12M | -$56.31M | -$43.62M | -$22.21M | -$16.52M | — |
| Net Income | -$28.92M | -$93.44M | -$62.68M | -$55.28M | -$43.51M | -$22.13M | -$16.31M | — |
| EPS (Diluted) | $-18.62 | $-71.75 | $-1.26 | $-1.83 | $-3.35 | — | — | — |
| Total Assets | $36.11M | $66.35M | $142.60M | $109.97M | $54.87M | $80.83M | $14.96M | — |
| Total Liabilities | $46.83M | $54.75M | $53.18M | $29.21M | $20.55M | $6.34M | $7.63M | — |
| Shareholders' Equity | -$10.72M | $11.59M | $89.42M | $80.75M | $34.32M | $74.49M | -$123.34M | -$107.07M |
| Cash & Equivalents | $15.89M | $40.58M | $22.35M | $32.55M | $45.75M | $74.59M | $9.81M | — |
| Operating Cash Flow | -$28.86M | -$70.01M | -$63.30M | -$43.38M | -$25.82M | -$21.14M | -$13.75M | — |
| Capital Expenditures | $116.0K | $2.34M | $1.05M | $164.0K | $3.38M | $1.77M | $211.0K | — |
| Shares Outstanding | 1.77M | 1.31M | 57.21M | 31.83M | 13.01M | 12.93M | 230.9K | — |